“This issuance follows our prior patents related to the methods of treating post-operative pain and edema,” said Dr. Nev Zubcevik, Endonovo’s chief medical officer and Harvard trained physical medicine and rehabilitation specialist. “The SofPulse technology is research proven and universally applicable to inflammatory conditions. Our preliminary research in the field of Autoimmune Encephalomyelitis, the inflammatory autoimmune model of multiple sclerosis, reveals significant change in the EAE score of treated animals when compared to sham. We are looking forward to expanding our technology applications into neuroinflammatory disorders; we believe our growing patent portfolio reinforces Endonovo’s leadership position in utilizing SofPulse to address pain while also underscoring the pioneering nature of the company’s Pulsed Electromagnetic Field-based (PEMF) Electroceuticals.”
CEO Alan Collier stated, “Our platform provides a unique opportunity for understanding the benefits Electroceuticals can deliver in a wide range of areas. Over the course of the past three years, Endonovo has grown its intellectual property in a rapid and methodical manner and we believe well positions us to extend our advantage in harnessing the power of Pulsed Electromagnetic Field (PEMF) Electroceuticals.”
the United States Patent and Trademark Office (USPTO) also issued the company U.S. Patent No. 15217855, which is directed to the usage of an apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke.
Collier said, “We are extremely pleased with the continued development and expansion of our patent portfolio. This new issuance continues to expand the breadth and depth of our SofPulse unit intellectual property portfolio and the issuance of this patent is another step in the development of a robust patent portfolio relating to SofPulse.”
Zubcevik stated, “Endonovo’s Electroceuticals are electronic devices designed to improve healing by mitigating underlying etiology of inflammation and swelling in tissues. Pulsed Electromagnetic Field-based (PEMF) Electroceuticals which use a unique electromagnetic field to deliver stimulation to tissues via induction, function by accelerating the production of the endogenous constitutive nitric oxide synthesis, improving anti-inflammatory mechanisms. Our published data in the Journal of Translational Stroke Research by the team at the University of New Mexico Health Sciences Center shows significant reduction of ischemic infarct size in PEMF-treated animals as compared to controls as seen on MRI. In addition, neuroinflammation, evaluated by using specialized cytokine/chemokine PCR array demonstrated that the SofPulse PEMF significantly reduced gene expression encoding for the major pro-inflammatory cytokine IL-1α, while expression of major anti-inflammatory IL-10 was significantly increased. Every year, more than 795,000 people in the United States have a stroke. About 87 percent of all strokes are ischemic strokes. We are thrilled to the future potential the SofPulse may have by reducing the burden of ischemic strokes and improving outcomes. In management’s opinion, this patent provides important coverage for SofPulse as we continue to address the tremendous patient needs that exist.”